Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have been assigned an average rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $48.40.

A number of research firms have issued reports on AAPG. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Rodman & Renshaw started coverage on Ascentage Pharma Group International in a report on Tuesday. They issued a “buy” rating and a $48.00 price objective for the company. Oppenheimer started coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price on the stock. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a research report on Monday, November 24th. Finally, BTIG Research assumed coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 price target for the company.

Ascentage Pharma Group International Stock Down 2.1%

Shares of AAPG opened at $27.77 on Wednesday. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. Ascentage Pharma Group International has a one year low of $16.50 and a one year high of $48.45. The stock has a 50 day moving average price of $29.97 and a 200 day moving average price of $36.01.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AAPG. UBS Group AG raised its position in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the last quarter. XY Capital Ltd increased its stake in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the period. Tema Etfs LLC acquired a new position in Ascentage Pharma Group International in the 2nd quarter valued at approximately $610,000. Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International in the 2nd quarter valued at approximately $391,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth approximately $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.